CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast

Indian Journal of Medical Research

Volumn 140, Issue September, 2014, Pages 361-369

  Rathore, Ankita Singh ^a   Kumar, Sandeep ^a,b   Konwar, Rituraj ^c   Makker, Annu ^a   Negi, M P S ^c   Goel, Madhu Mati ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Breast cancer; CD3; CD4; CD8; Ductal carcinoma; Tumour infiltrating lymphocytes

Indexed keywords

CD3 ANTIGEN; TUMOR MARKER;

ADULT; AGED; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; FEMALE; HUMAN; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84908176160     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2: 133-40.
2. Ray A, Mitra AB. Estrogen and breast cancer. ICMR Bull 2003; 33: 13-24.
3. Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol 2010; 23 (Suppl 2): S60-4.
4. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008; 14: 5220-7.
5. Ancuta E, Ancuta C, Zugun-Eloae F, Iordache C, Chirieac R, Carasevici E. Predictive value of cellular immune response in cervical cancer. Rom JMorpholEmbryol 2009; 50: 651-5.
6. Strater J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T, et al. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 2005; 54: 661-5.
7. Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB. Intratumoural CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 2004; 10: 4450-6.
8. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61: 3932-6.
9. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, et al. CD8 tumour-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 2007; 104: 3967-72.
10. Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007; 13: 388-97.
11. Haanen JB, Baars A, Gomez R, Weder P, Smits M, de Gruijl TD, et al. Melanoma-specific tumour-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 2006; 55: 451-8.
12. Nedergaard BS, Ladekarl M, Thomsen HF, Nyengaard JR, Nielsen K. Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer. Br J Cancer 2007; 97: 1135-8.
13. Marsigliante S, Biscozzo L, Marra A, Nicolardi G, Leo G, Lobreglio GB, et al. Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens. Cancer Lett 1999; 139: 33-41.
14. Rajjoub S, Basha SR, Einhorn E, Cohen MC, Marvel DM, Sewell DA. Prognostic significance of tumour-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J 2007; 86: 506-11.
15. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009; 137: 1270-9.
16. Beatty G, Paterson Y. IFN-gamma-dependent inhibition of tumour angiogenesis by tumour-infiltrating CD4+ T cells requires tumour responsiveness to IFN-gamma. J Immunol 2001; 166: 2276-82.
17. Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T. The role of tumour- specific Lyt-1+2-T cells in eradicating tumour cells in vivo. I. Lyt-1+2-T cells do not necessarily require recruitment of host’s cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol 1984; 133: 1671-6.
18. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumour infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538-43.
19. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, et al. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 2008; 14: 2028-35.
20. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-77.
21. Guo X, Fan Y, Lang R, Gu F, Chen L, Cui L, et al. Tumour infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast. Mod Pathol 2008; 21:1101-7.
22. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Pathologists Practice Guidelines update. J Clin Oncol 2013; 31: 3997-4013.
23. Yu P, Fu YX. Tumour-infiltrating T lymphocytes: friends or foes? Lab Invest 2006; 86: 231-45.
24. Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, et al. The prognostic role of tumour-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res 2009; 29: 2445-51.
25. La Rocca G, Anzalone R, Corrao S, Magno F, Rappa F, Marasa S, et al. CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome. Histopathology 2008; 52: 203-12.
26. Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, et al. Tumour-infiltrating lymphocytes, tumour characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol 2013; 36: 224-31.
27. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103.
28. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, et al. HLA class I antigen processing machinery component expression and intratumoural T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008; 14: 3372-9.
29. Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, et al. Prognostic implications of type and density of tumour- infiltrating lymphocytes in gastric cancer. Br J Cancer 2008; 99: 1704-11.
30. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13: 902-11.
31. Zingg U, Montani M, Frey DM, Dirnhofer S, Esterman AJ, Went P, et al. Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur J Surg Oncol 2010; 36: 670-7.